Your search for oral corticosteroids returned 11 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Older than 2 years remove
Drugs in the Pipeline remove

Your search for oral corticosteroids returned 11 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Oral Tyrosine Kinase Inhibitor Effective in Severe Asthma Trial

Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
Drugs in the Pipeline

Dupilumab Gets Priority Review for Adolescent Atopic Dermatitis

Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.
Drugs in the Pipeline

Tezepelumab Gets Breakthrough Therapy Designation for Severe Asthma

The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.
Drugs in the Pipeline

Benralizumab Use Cuts Need for Oral Steroids in Severe Asthma

The primary endpoint was met with 75% of the benralizumab group reducing their OCS doses compared to 25% in the placebo group. Additionally, 52% of the benralizumab group who had optimized baseline OCS doses of ≤12.5mg/d were able to completely stop OCS use.
Drugs in the Pipeline

Phase 3 Study Results for Severe Eosinophilic Asthma Drug

GlaxoSmithKline announced that the primary endpoint for its Phase 3 study of mepolizumab was met for the reduction in the frequency of exacerbations, in patients with severe eosinophilic asthma.